Printer Friendly

Prompt use of medications may slow BPH progression.

Early use of drugs known as 5-alpha reductase inhibitors (5-ARIs) may reduce the risk of clinical progression in men taking an alpha-blocker medication for benign prostatic hyperplasia (BPH, or enlarged prostate), suggests a study in the August issue of Pharmacy & Therapeutics. The 5-ARIs include finasteride (Proscar) and dutasteride (Avodart), while alpha-blockers include alfuzosin (Uroxatral), tamsulosin (Flomax), and si.lodosin (Rapaflo). Researchers analyzed data on 8,617 men with BPH, dividing them into those who began 5-ARI therapy early (within 30 days of starting an alpha-blocker) and those on a delayed regimen (30-180 days after starting an alpha-blocker). They assessed the likeli-hood that the men's BPH would progress to acute urinary retention (a sudden inability to urinate) or necessitate surgery over a one-year period. Compared to men receiving delayed 5-AKI therapy, those given early treatment were nearly 5 percent less likely to experience clinical progression of their BPH, 3.6 percent less likely to develop acute urinary retention, and 2 percent less likely to require surgery, the study found. The take-home message: If you have BPH, ask your doctor about adding a 5-ARI to alpha-blocker therapy to reduce your risk of progression.


COPYRIGHT 2011 Belvoir Media Group, LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:NEWS BRIEFS
Publication:Men's Health Advisor
Article Type:Brief article
Geographic Code:1USA
Date:Dec 1, 2011
Previous Article:Combo of lifestyle factors greatly trims diabetes risk.
Next Article:High-normal blood pressure increases stroke risk.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters